N/A N=30 Iyengar Yoga for Young People With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Health Related Quality of Life - Short Form-36 (SF-36) — 59.1; 59.3; 60.1; 47.0 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 The Evaluation of Belimumab in Myasthenia Gravis (MG)
Myasthaenia Gravis
Primary: Mean Change From Baseline for Quantitative Myasthenia Gravis (QMG) Score at Week 24 — -2.37; -4.21 Units on a scale — p=0.256
Phase 1 N=36 Food Effect Study of Febuxostat XR in Healthy Participants
Gout
Primary: Cmax: Maximum Observed Plasma Concentration for Febuxostat XR 80 mg in Fed (Regimen A) and Fasted (Regimen C) States — 1020.0000; 1531.6286 ng/mL
Phase 2 N=16 Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
Hyperoxaluria · Nephrolithiasis
Primary: Change From Baseline Period to Treatment Period 24-hour Urinary Oxalate Excretion — -13.92 mg/day
Phase 2 N=56 Ranibizumab and Bevacizumab for Diabetic Macular Edema
Diabetic Macular Edema
Primary: Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) From Baseline to 36 Weeks (Crossover Phase of the Study) — 5.3; 6.6…
Phase 2 N=56 Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Overall Survival — 5.7 months — p=0.4
Early Phase 1 N=19 A Study of Dog Adoption in Veterans With Posttraumatic Stress Disorder (PTSD)
Posttraumatic Stress Disorder (PTSD)
Primary: Change in PTSD Checklist (PCL-5) Score Between Baseline and 3-month Follow-up — -15.20; -7.77 units on a scale — p=0.141
N/A N=42 Post-Approval Clinical Study to Evaluate the Calcivis Caries Activity Imaging System
Dental Caries
Primary: Percentage Agreement of Sound/Unsound Teeth Between ICDAS Score and Calcivis System — 72.3 percentage agreement — p=<0.001
Phase 2 N=70 Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Low-grade B Cell Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma Where Hematopoietic Stem Cell Transplantation is Not Indicated
Primary: Complete Response Rate (CR + CRu) Based on International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas (1999)(IWRC) — 67.8; 70.0; 68.1 percentage…
Phase 3 N=51 Randomized, Controlled Study of CF Patients Between 3 Months and Less Than 7 Years
Treatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis Patients
Primary: Percentage of Participants P Aeruginosa-free After Completion of the First Treatment Cycle — 84.6; 24.0 Percentage of participants — p=<0.001
N/A N=36 Exercise in Obese Diabetic Patients With Chronic Kidney Disease
Chronic Kidney Disease
Primary: Change in Proteinuria — -34; -133 mg/g creatinine — p=0.04
N/A N=242 INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
Carcinoma, Renal Cell · Lymphoma, Mantle-Cell
Primary: Progression-free Survival (PFS) — 4.04; 7.467; 13.233 months
Phase 4 N=18 Propranolol and Botulinum Toxin for Essential Vocal Tremor
Essential Vocal Tremor · Essential Voice Tremor · Essential Tremor
Primary: Change in Quality of Life in Essential Tremor (QUEST) Questionnaire Score — 39.41; 29.50; 23.60 units on a scale
Phase 2 N=57 Modafinil, Sleep Architecture and Cocaine Relapse
Cocaine Dependence
Primary: %Cocaine Free Urines — 52; 26 percent
Phase 3 N=188 A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients
Liver Transplantation
Primary: Change From Baseline (Randomization) in Renal Function — -13.29; 1.05 mL/min/1.73m^2 — p=<0.0001